Sonoma Biotherapeutics rallies $265m Series B
Sonoma Biotherapeutics, a developer of regulatory T cell therapies, has secured $265 million in Series B financing.
4 August 2021•1 min read
Sonoma Biotherapeutics, a developer of regulatory T cell therapies, has secured $265 million in Series B financing.
Inovia hits $200m in first close for sixth early-stage fund
19 October 2026 · 4 mins read
San Joaquin County to slow venture commitments
15 October 2026 · 2 mins read
DOWNLOAD: Fundraising holds steady in Q3
14 October 2026 · 2 mins read
Why Endeavor Catalyst is betting big on Southeast Asia
8 October 2026 · 4 mins read
Dig's new fund bets on infrastructure built around foundation models
6 October 2026 · 4 mins read
Meet venture capital’s 2026 Women of Influence
5 October 2026 · 4 mins read
Eyeing opportunities and how the Women of Influence see trends developing
5 October 2026 · 3 mins read
